Dr. Matthew A. Cunningham, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,653
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Florida College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME114768 -
Retina Specialist (Ophthalmology) Physician
FL license ME114768
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Orlando Orlando, FL
Medical groups
- Retina Vitreous Consultants (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,653
- Services billed
- 41,859
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 19,440 | 81 |
| Injection, aflibercept, 1 mg | 2,858 | 322 |
| Imaging of retina | 2,788 | 1,149 |
| Injection of drug into eye | 2,409 | 581 |
| Photography of the retina | 1,788 | 1,559 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,501 | 89 |
| Injection, ranibizumab, 0.1 mg | 1,358 | 84 |
| Established patient complete exam of visual system | 1,326 | 1,144 |
| Established patient office or other outpatient visit, 20-29 minutes | 502 | 383 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 420 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Orlando, FL | 331 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Orlando, FL | 188 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Orlando, FL | 168 |
| Ketorolac Tromethamine Other prescribers in Orlando, FL | 161 |
| Latanoprost Other prescribers in Orlando, FL | 136 |
| Brimonidine Tartrate Other prescribers in Orlando, FL | 108 |
| Eylea (aflibercept) | 106 |
| Timolol Maleate Other prescribers in Orlando, FL | 62 |
| Dorzolamide Hcl Other prescribers in Orlando, FL | 32 |
| Atropine Sulfate | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 72 payments worth $78,505 in total to this clinician.
| Genentech USA, Inc. | $18,892 |
|---|---|
| Apellis Pharmaceuticals, Inc. | $18,043 |
| Regeneron Healthcare Solutions, Inc. | $17,702 |
| Astellas Pharma US Inc | $13,922 |
| Alcon Vision LLC | $3,157 |
| Ocular Therapeutix, Inc. | $2,438 |
| Ani Pharmaceuticals, Inc. | $2,274 |
| Alcon Research LLC | $1,860 |
| Compensation for services other than consulting (speaking, faculty) | $27,202 |
|---|---|
| Consulting Fee | $25,655 |
| Speaking at a medical education program | $15,771 |
| Travel and Lodging | $5,607 |
| Food and Beverage | $2,244 |
| Honoraria | $2,025 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee | $18,500 |
| Apellis Pharmaceuticals, Inc. Nov 25, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $8,041 |
| Astellas Pharma US Inc Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,640 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,640 |
| Astellas Pharma US Inc Nov 15, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $5,000 |
| Apellis Pharmaceuticals, Inc. Oct 26, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $4,730 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,309 |
| Ani Pharmaceuticals, Inc. Aug 7, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $2,025 |
| Alcon Research LLC Aug 7, 2025 | Consulting Fee UNITY · Ophthalmology | $1,860 |
All 30 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,640 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to PALM BEACH GARDENS, FL · in-kind | $1,055 |
| Apellis Pharmaceuticals, Inc. Nov 25, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $8,041 |
| Astellas Pharma US Inc Nov 15, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $5,000 |
| Astellas Pharma US Inc Nov 15, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Lake Buena Vista, FL | $431 |
| Astellas Pharma US Inc Nov 15, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to Lake Buena Vista, FL | $53.20 |
| Ocular Therapeutix, Inc. Nov 13, 2025 | Consulting Fee | $1,600 |
| Apellis Pharmaceuticals, Inc. Nov 6, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Marietta, GA · in-kind | $548 |
| Apellis Pharmaceuticals, Inc. Nov 6, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Marietta, GA · in-kind | $511 |
| Apellis Pharmaceuticals, Inc. Nov 6, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Marietta, GA · in-kind | $429 |
| Apellis Pharmaceuticals, Inc. Nov 6, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Marietta, GA · in-kind | $374 |
| Apellis Pharmaceuticals, Inc. Nov 6, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Marietta, GA · in-kind | $85.99 |
| Regeneron Healthcare Solutions, Inc. Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $2,309 |
| Apellis Pharmaceuticals, Inc. Oct 26, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $4,730 |
| Apellis Pharmaceuticals, Inc. Oct 26, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Orlando, FL | $23.80 |
| Apellis Pharmaceuticals, Inc. Oct 1, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $1,500 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee | $18,500 |
| Ani Pharmaceuticals, Inc. Aug 7, 2025 | Honoraria ILUVIEN · treatment of diabetic macular edema in patients who have been previously treated | $2,025 |
| Alcon Research LLC Aug 7, 2025 | Consulting Fee UNITY · Ophthalmology | $1,860 |
| Alcon Vision LLC Aug 7, 2025 | Consulting Fee UNITY · Ophthalmology | $1,395 |
| Alcon Vision LLC Jul 10, 2025 | Consulting Fee | $500 |
| Regeneron Healthcare Solutions, Inc. Jun 20, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $1,614 |
| Astellas Pharma US Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $1,000 |
| Astellas Pharma US Inc Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) Izervay · Ophthalmology | $6,000 |
| Astellas Pharma US Inc Apr 17, 2025 | Travel and Lodging Izervay · Ophthalmology · travel to West Palm Beach, FL | $1,101 |
| Ocular Therapeutix, Inc. Mar 27, 2025 | Consulting Fee | $800 |
| Apellis Pharmaceuticals, Inc. Mar 25, 2025 | Speaking at a medical education program Syfovre · Ophthalmology | $1,500 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) EYLEA HD · OPHTHALMOLOGY | $5,640 |
| Regeneron Healthcare Solutions, Inc. Mar 4, 2025 | Travel and Lodging EYLEA HD · OPHTHALMOLOGY · travel to TAMPA, FL · in-kind | $995 |
| Alcon Vision LLC Jan 23, 2025 | Consulting Fee | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $932,857 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - New Day Study
Ani Pharmaceuticals, Inc. - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - Constance Faricimab in nAMD patients
Genentech, Inc. - Faricimab for Under represented Patients with DME
Genentech, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degener…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.